Available at: Summary Keywords liver transplantation, obesity, metabolic syndrome, antidiabetic medication, weight loss, glucose-lowering medication Citation Atthota S, Joyal K, Cote M, Scalzo R, Singh R, Consul N, Kilcoyne A, Bethea ED and Dageforde LA (2023) Modern glucose-lowering drugs in liver transplant recipients: improvement in weight, glycemic control, and potentially allograft steatosis
While moderate alcohol consumption isnt absolutely prohibited, limiting or avoiding alcohol is generally sensible if you have fatty liver disease
It was designed to treat diabetes
And the ones that it were approved so far in certain countries, like the US are so questionable as to the safety and efficacy
Inclusion criteria required adults aged 1875 with UC diagnosis over 90 days, total MS of 5 or higher, MES of 2 or higher, and RBS of 1 or higher, while excluding severe extensive colitis requiring hospitalization, fulminant colitis, CD, and recent toxic megacolon
The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Companys filings with the Securities and Exchange Commission, including under Item 1A, Risk Factors in the Companys most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K
